

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective April 1, 2021 – Part 2

This article is a continuation of the previously published *Quarterly Pharmacy Changes Part 1 article*. While that part 1 article included the drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates, this part 2 version contains the more recent coverage additions, utilization management updates and any other updates to the pharmacy program.

DRUG LIST CHANGES

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of Texas (BCBSTX) drug lists.

Please note: Revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) were included in the *Quarterly Pharmacy Changes Part 1 article*. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes.


Changes effective April 1, 2021 are outlined below.

Drug List Coverage Additions - As of April 1, 2021

| Drug ¹ | Drug Class/Condition Used For | | | |
|--|--|--|--|--|
| Basic, Basic Annual, Multi-Tier Basic, Multi-Tier Basic Annual, Enhanced, Enhanced Annual, | | | | |
| Multi-Tier Enhanced and Multi-Tier Enhanced Annual Drug Lists | | | | |
| EPCLUSA (sofosbuvir-velpatasvir tab 200-50 mg) | Hepatitis C | | | |
| RETACRIT (epoetin alfa-epbx inj 20000 unit/ml) | Anemia | | | |
| RETEVMO (selpercatinib cap 40 mg, 80 mg) | Cancer | | | |
| | | | | |
| Balanced, Performance, Performance Annual a | nd Performance Select Drug Lists | | | |
| asenapine maleate sl tab 2.5 mg, 5 mg, 10 mg (base | Bipolar Disorder, Schizophrenia | | | |
| equiv) (generic for SAPHRIS) | | | | |
| CYSTADROPS (cysteamine hcl ophth soln 0.37% (base | Cystinosis | | | |
| equivalent)) | | | | |
| deferiprone tab 500 mg (generic for FERRIPROX) | Chronic Iron Overload | | | |
| DIFICID (fidaxomicin for susp 40 mg/ml) | Infections | | | |
| dimethyl fumarate capsule dr starter pack 120 mg & 240 | Relapsing Multiple Sclerosis | | | |
| mg (generic for TECFIDERA STARTER PACK) | | | | |
| efavirenz-emtricitabine-tenofovir df tab 600-200-300 mg | HIV | | | |
| (generic for ATRIPLA) | | | | |
| emtricitabine-tenofovir disoproxil fumarate tab 200-300 | HIV/HIV Prophylaxis | | | |
| mg | | | | |
| ENSPRYNG (satralizumab-mwge subcutaneous soln | Neuromyelitis Optica Spectrum Disorder | | | |
| pref syringe 120 mg/ml) | (NMOSD) | | | |
| EPCLUSA (sofosbuvir-velpatasvir tab 200-50 mg) | Hepatitis C | | | |
| fosfomycin tromethamine powd pack 3 gm (base | Infections | | | |
| equivalent) (generic for MONUROL) | | | | |
| GAVRETO (pralsetinib cap 100 mg) | Cancer | | | |
| icosapent ethyl cap 1 gm (generic for VASCEPA) | Hypertriglyceridemia | | | |
| INQOVI (decitabine-cedazuridine tab 35-100 mg) | Cancer | | | |
| ivermectin lotion 0.5% (generic for SKLICE) | Lice | | | |



| LAMPIT (nifurtimox tab 30 mg, 120 mg) | Chagas Disease | |
|---|---------------------------------------|--|
| lapatinib ditosylate tab 250 mg (base equiv) (generic for | Cancer | |
| TYKERB) | Ganoci | |
| LEVOTHYROXINE SODIUM (levothyroxine sodium cap | Hypothyroidism | |
| 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 | ,, , | |
| mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg) | | |
| (authorized generic for TIROSINT) | | |
| MENQUADFI (meningococcal (a, c, y, and w-135) | Meningococcal Vaccine | |
| conjugate vaccine inj) | 3 | |
| MYCAPSSA (octreotide acetate cap delayed release 20 | Acromegaly | |
| mg) | | |
| nitazoxanide tab 500 mg (generic for ALINIA) | Parasitic Infections | |
| norethindrone ace & ethinyl estradiol tab 1 mg-20 mcg, | Oral Contraceptive | |
| 1.5 mg-30 mcg | · | |
| norethindrone ace & ethinyl estradiol-fe tab 1 mg-20 mcg, | Oral Contraceptive | |
| 1.5 mg-30 mcg | · | |
| ONUREG (azacitidine tab 200 mg, 300 mg) | Cancer | |
| PALFORZIA INITIAL DOSE ESCALATION (peanut | Peanut Allergy | |
| powder-dnfp starter pack 0.5 & 1 & 1.5 & 3 & 6 mg) | | |
| PALFORZIA LEVEL 1 (peanut powder-dnfp cap sprinkle | Peanut Allergy | |
| pack 3 x 1 mg (3 mg dose)) | , , | |
| PALFORZIA LEVEL 2 (peanut powder-dnfp cap sprinkle | Peanut Allergy | |
| pack 6 x 1 mg (6 mg dose)) | o, | |
| PALFORZIA LEVEL 3 (peanut powder-dnfp pack 2 x 1 | Peanut Allergy | |
| mg & 10 mg (12 mg dose)) | , , | |
| PALFORZIA LEVEL 4 (peanut powder-dnfp cap sprinkle | Peanut Allergy | |
| pack 20 mg (20 mg dose)) | o, | |
| PALFORZIA LEVEL 5 (peanut powder-dnfp cap sprinkle | Peanut Allergy | |
| pack 2 x 20 mg (40 mg dose)) | , , , , , , , , , , , , , , , , , , , | |
| PALFORZIA LEVEL 6 (peanut powder-dnfp cap sprinkle | Peanut Allergy | |
| pack 4 x 20 mg (80 mg dose)) | | |
| PALFORZIA LEVEL 7 (peanut powder-dnfp pack 20 mg | Peanut Allergy | |
| & 100 mg (120 mg dose)) | | |
| PALFORZIA LEVEL 8 (peanut powder-dnfp pack 3 x 20 | Peanut Allergy | |
| mg & 100 mg (160 mg dose)) | | |
| PALFORZIA LEVEL 9 (peanut powder-dnfp pack 2 x 100 | Peanut Allergy | |
| mg (200 mg dose)) | | |
| PALFORZIA LEVEL 10 (peanut powder-dnfp pack 2 x 20 | Peanut Allergy | |
| mg & 2 x 100 mg (240 mg dose)) | | |
| PALFORZIA LEVEL 11 (MAINTENANCE) (peanut | Peanut Allergy | |
| allergen powder-dnfp maintenance packet 300 mg) | | |
| PALFORZIA LEVEL 11 (TITRATION) (peanut allergen | Peanut Allergy | |
| powder-dnfp titration packet 300 mg) | | |
| PFIZER-BIONTECH COVID-19 VACCINE (covid-19 | COVID-19 Vaccine | |
| (sars-cov-2) mrna vacc-pfizer im susp 30 mcg/0.3 ml) | | |
| PREVIDENT RINSE (sodium fluoride rinse 0.2%) | Dental Caries Prophylaxis | |
| RETACRIT (epoetin alfa-epbx inj 20000 unit/ml) | Anemia | |
| rufinamide susp 40 mg/ml (generic for BANZEL susp) | Seizures | |
| SEVENFACT (coagulation factor viia (recom)-jncw for inj | Hemophilia | |
| 1 mg (1000 mcg), 5 mg (5000 mcg)) | | |
| tobramycin nebu soln 300 mg/4 ml (generic for | Cystic Fibrosis | |
| BETHKIS) | | |
| TOLVAPTAN (tolvaptan tab 15 mg) (authorized generic | Hyponatremia | |
| for SAMSCA) | | |



| TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol | Chronic Obstructive Pulmonary Disease | |
|--|--|--|
| aepb 200-62.5-25 mcg/inh) | | |
| TRULICITY (dulaglutide soln pen-injector 4.5 mg/0.5 ml) | Diabetes | |
| XYWAV (calcium, mag, potassium, & sod oxybates oral | Cataplexy/Excessive Daytime Sleepiness | |
| soln 500 mg/ml) | | |
| | | |
| Balanced Drug I | | |
| ALKINDI SPRINKLE (hydrocortisone cap sprinkle 0.5 | Adrenocortical Insufficiency | |
| mg, 1 mg, 2 mg, 5 mg) | | |
| CONJUPRI (levamlodipine maleate tab 2.5 mg, 5 mg) | Hypertension | |
| diphenhydramine hcl liquid 12.5 mg/5 ml | Allergic Conditions | |
| GIMOTI (metoclopramide hcl nasal spray 15 mg/act) | Diabetic Gastroparesis | |
| HEMADY (dexamethasone tab 20 mg) | Cancer | |
| lamotrigine tab disint 25 (14) & 50 mg (14) & 100 mg (7) | Seizures | |
| kit (generic for LAMICTAL ODT KIT) | | |
| MECLIZINE HYDROCHLORIDE (meclizine hcl tab 50 | Nausea/Motion Sickness | |
| mg) | | |
| NEONATAL 19 (prenatal vitamin-folic acid tab 1 mg) | Prenatal Vitamin | |
| NEONATAL COMPLETE (prenatal vit w/ fe fumarate-fa | Prenatal Vitamin | |
| tab 29-1 mg) | | |
| NEONATAL FE (prenatal vitamin w/ iron-folic acid tab 90- | Prenatal Vitamin | |
| 1 mg) | | |
| NEONATAL/DHA (prenatal mv w/fe fum-fa tab 29-1 mg & | Prenatal Vitamin | |
| dha cap 200 mg pack) | | |
| norethindrone ace-ethinyl estradiol-fe cap 1 mg-20 mcg | Oral Contraceptive | |
| (24) (generic for TAYTULLA) | | |
| ONGENTYS (opicapone cap 50 mg) | Parkinson's Disease | |
| timolol maleate preservative free ophth soln 0.5% | Glaucoma, Ocular Hypertension | |
| (generic for TIMOPTIC OCUDOSE) | | |
| UPNEEQ (oxymetazoline hcl ophth soln 0.1%) | Acquired Blepharoptosis | |
| WESTAB PLUS (prenatal vit w/ fe fumarate-fa tab 27-1 | Prenatal Vitamin | |
| mg) | | |
| WESTGEL DHA (prenat w/o a w/fecbn-methylf-fa-dha | Prenatal Vitamin | |
| cap 31-0.6-0.4-200 mg) | | |
| zileuton tab er 12hr 600 mg, sr 12hr 600 mg | Asthma | |
| ZYFLO (zileuton tab 600 mg) | Asthma | |

¹Third-party brand names are the property of their respective owner.

Drug List Updates (Coverage Tier Changes) - As of April 1, 2021

| Drug List opuates (Coverage Tier Changes) - As of April 1, 2021 | | | | |
|---|-----------------------|-------------------------------|--|--|
| Drug ¹ | New Lower Tier | Drug Class/Condition Used For | | |
| Balanced, Performance, Performance Annual and Performance Select Drug Lists | | | | |
| alendronate sodium oral soln 70 mg/75 | Non-Preferred Generic | Osteoporosis | | |
| ml | | • | | |
| diltiazem hcl cap er 24hr 120 mg | Preferred Generic | Hypertension | | |
| diltiazem hcl cap er 24hr 180 mg, 24hr | Non-Preferred Generic | Hypertension | | |
| 240 mg | | | | |
| ferrous sulfate syrup 300 mg/5 ml (60 | Non-Preferred Generic | Iron Deficiency | | |
| mg/5 ml elemental fe) | | | | |
| leucovorin calcium tab 10 mg, 15 mg | Non-Preferred Generic | Toxicity treatment and | | |
| | | prophylaxis, Cancer | | |
| oxazepam cap 10 mg, 15 mg, 30 mg | Non-Preferred Generic | Anxiety, alcohol withdrawal | | |
| RETEVMO (selpercatinib cap 40 mg, 80 | Preferred Brand | Cancer | | |
| mg) | | | | |



| Balanced Drug List | | | | |
|--|-----------------------|-------------------------------|--|--|
| baclofen tab 5 mg | Non-Preferred Generic | Muscle spasms/spasticity | | |
| hydrocodone-acetaminophen soln 10- | Non-Preferred Generic | Pain | | |
| 325 mg/15 ml | | | | |
| pseudoephed-bromphen-dm syrup 30-2- | Non-Preferred Generic | Cough/Cold | | |
| 10 mg/5 ml | | | | |
| timolol maleate ophth gel forming soln | Non-Preferred Generic | Glaucoma, ocular hypertension | | |
| 0.25%, 0.5% (generic for TIMOPTIC-XE) | | | | |

¹Third-party brand names are the property of their respective owner.

UTILIZATION MANAGEMENT PROGRAM CHANGES

- Effective **Feb. 1, 2021**, the Opioid Antidote Prior Authorization (PA) program retired due to the discontinuation of the product Evzio.
- Effective April 1, 2021, the following changes will be applied:
 - The Combination NSAIDs standard PA program will no longer apply to the Performance and Performance Annual Drug Lists.
 - The Somatostatins Specialty PA program will be added to the following drug lists as a standard Specialty PA program.
 - This program will include the target drugs Bynfezia, Mycapssa and Somavert that will apply to the Balanced, Performance, Performance Annual and Performance Select Drug Lists. Please note: Prior to April 1, 2021, members needed a prior authorization approval for coverage consideration. The addition of this program will not be a new change for these members.
 - The target drugs Mycapssa and Somavert will also apply to the Basic, Basic Annual, Enhanced and Enhanced Annual Drug Lists. Members will need a prior authorization approval for coverage consideration. The addition of this program will not be a new change for these members.
 - The Sodium Oxybate Specialty PA program will change its name to Oxybate. The targeted medications and the intent of the program criteria remain the same.
 - The target drugs of the Atypical Antipsychotics Step Therapy (ST) program will be recategorized into two separate programs:
 - Abilify Maintena, Aristada, Aristada Initio, Invega Sustenna, Invega Trinza, Perseris, Risperdal Consta and Zyprexa Relprevv will be included in the Atypical Antipsychotics – Extended Maintenance Agents ST program. This program will be added to the Basic, Basic Annual, Enhanced and Enhanced Annual Drug Lists.
 - Abilify, Abilify Mycite, Caplyta, Clozapine ODT, Clozaril, Fanapt, Geodon, Invega, Latuda, Rexulti, Risperdal, Risperdal M-Tab, Risperidone ODT, Saphris, Secuado, Seroquel, Seroquel XR, Versacloz, Vraylar, Zyprexa and Zyprexa Zydis will be included in the Atypical Antipsychotics ST program. This program will be added to all drug lists as a standard ST program.

For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.



If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit *bcbstx.com* and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.

Reminder: Split Fill Program Available to Select Members

BCBSTX offers its members and groups a Split Fill program to reduce waste and help avoid costs of select specialty medications that may go unused. Members new to therapy (or have not had claims history within the past 120 days for the drug) are provided partial, or "split," prescription fills for up to three months.

The Split Fill Program applies to a specific list of drugs known to have early discontinuation or dose modification. You can view the current list of drugs and find more information on the Split Fill Program on our Provider website.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Updates to the List of Drugs Covered Without Cost Sharing

Starting April 1, 2021, BCBSTX will be offering additional single-agent statin and HIV Pre-exposure Prophylaxis (PrEP) coverage for members with an ACA-compliant plan. Atorvastatin tablets 10 mg and 20 mg (Lipitor) and emtricitabine-tenofovir disoproxil fumarate tab 200-300 mg (Truvada) will be available at \$0 if members meet the conditions set under ACA. This addition is based on the United States Preventive Services Task Force recommendation.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSTX contracts with Prime to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.